Skip to main content
Top
Published in: Annals of Nuclear Medicine 9/2017

01-11-2017 | Original Article

Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18FDG-PET/CT according to ΔSUVmax, Deauville 5-point scale and IHP criteria

Authors: Emine Göknur Isik, Serkan Kuyumcu, Rejin Kebudi, Yasemin Sanli, Zeynep Karakas, Fatma Betul Cakir, Seher Nilgün Unal

Published in: Annals of Nuclear Medicine | Issue 9/2017

Login to get access

Abstract

Objective

Minimizing side effects by using response-adopted therapy strategies plays an important role in the management of pediatric Hodgkin lymphoma (HL); however, the criteria for the definition of adequate or inadequate response are controversial. The aim of this study is to compare different methods of interpretation of 18F-FDG-PET/CT (PET) in the prediction of disease outcome in order to determine the optimum method in this regard.

Methods

Baseline, interim and post-treatment PET scans of 72 children were interpreted according to revised International Harmonization Project criteria (IHP) and Deauville criteria. Cut-off values for changes in interim and post-treatment FDG uptake (ΔSUVmax) in the prediction of progression-free survival (PFS) were measured using ROC analysis. Quantitative and visual data were compared with each other in the prediction of PFS.

Results

Mean interim and post-treatment ΔSUVmax of the primary lesions were 77.4 ± 19.5 and 68.8 ± 30.4% and respective cut-off values were 82 and 73%. However, only post-treatment ΔSUVmax yielded statistically significant results in the prediction of 3-year PFS (p = 0.043). Interim ΔSUVmax was further analyzed according to the values reported in the literature (66 and 77%) yet statistically significant results were not reached (p = 0.604 and 0.431). For interim evaluation, IHP criteria was correlated to Deauville criteria (p = 0.002 and p = 0.001) and ΔSUVmax (p = 0.03), whereas for post-treatment evaluation, significant correlation with ΔSUVmax (p = 0.04) but marginally significant (p = 0.055 and p = 0.058) correlation with Deauville criteria were achieved. Overall, 1, 3 and 5-year PFS were 95.7 ± 0.2, 89.6 ± 0.4 and 80.8 ± 0.7%, respectively. All methods demonstrated comparable performance in the prediction of 3-year PFS; however, interim PET using Deauville criteria and post-treatment PET using IHP criteria were statistically significant. All methods demonstrated high negative-predictive value but substantially low positive-predictive value.

Conclusions

Deauville criteria are superior to other methods in the prediction of pediatric HL outcome using interim PET data. On the other hand, quantitative evaluation and visual evaluation by IHP can be used reliably at the end of the treatment. In this regard, we report the optimal cut-off value of SUVmax reduction as 73%.
Literature
1.
go back to reference Swerdlow AJ. Epidemiology of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):3–12.CrossRef Swerdlow AJ. Epidemiology of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):3–12.CrossRef
2.
go back to reference Jorgov L, Montravers F, Balogova S, Ragu C, Pacquement H, Leblanc T, et al. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18F-fluorodeoxyglucose on pre-treatment and on interim PET/CT. Eur J Nucl Med Mol Imaging. 2016;43(7):1220–30.CrossRefPubMed Jorgov L, Montravers F, Balogova S, Ragu C, Pacquement H, Leblanc T, et al. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18F-fluorodeoxyglucose on pre-treatment and on interim PET/CT. Eur J Nucl Med Mol Imaging. 2016;43(7):1220–30.CrossRefPubMed
3.
go back to reference Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMed Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMed
4.
go back to reference Kostakoglu L, Cheson BD. Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(5):1004–27.CrossRefPubMed Kostakoglu L, Cheson BD. Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(5):1004–27.CrossRefPubMed
5.
go back to reference Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, et al. Early chemotherapy intensification with BEACOPP in advanced stage Hodgkin lymphoma patients with an interim-PET positive after two ABVD courses. Br J Haematol. 2011;152(5):551–60.CrossRefPubMed Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, et al. Early chemotherapy intensification with BEACOPP in advanced stage Hodgkin lymphoma patients with an interim-PET positive after two ABVD courses. Br J Haematol. 2011;152(5):551–60.CrossRefPubMed
6.
go back to reference Körholz D, Kluge R, Wickmann L, Hirsch W, Lüders H, Lotz I, et al. Importance of F18-fluorodeoxy-d-2-glucose positron emission tomography (FDGPET) for staging und therapy control of Hodgkin’s lymphoma in childhood and adolescence—consequences for the GPOH-HD 2003 protocol. Onkologie. 2003;26(5):489–93.PubMed Körholz D, Kluge R, Wickmann L, Hirsch W, Lüders H, Lotz I, et al. Importance of F18-fluorodeoxy-d-2-glucose positron emission tomography (FDGPET) for staging und therapy control of Hodgkin’s lymphoma in childhood and adolescence—consequences for the GPOH-HD 2003 protocol. Onkologie. 2003;26(5):489–93.PubMed
7.
go back to reference Kluge R, Körholz D. Role of FDG-PET in staging and therapy of children with Hodgkin lymphoma. Klin Padiatr. 2011;223(6):315–9.CrossRefPubMed Kluge R, Körholz D. Role of FDG-PET in staging and therapy of children with Hodgkin lymphoma. Klin Padiatr. 2011;223(6):315–9.CrossRefPubMed
8.
go back to reference Kostakoglu L, Gallamini A. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift? J Nucl Med. 2013;54(7):1082–93.CrossRefPubMed Kostakoglu L, Gallamini A. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift? J Nucl Med. 2013;54(7):1082–93.CrossRefPubMed
9.
go back to reference Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91(4):475–81.PubMed Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91(4):475–81.PubMed
10.
go back to reference Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8.CrossRefPubMed Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8.CrossRefPubMed
11.
go back to reference Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257–60.CrossRefPubMed Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257–60.CrossRefPubMed
12.
go back to reference Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma. 2009;50(11):1761–4.CrossRefPubMed Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma. 2009;50(11):1761–4.CrossRefPubMed
13.
go back to reference Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol. 2006;28(5):300–6.CrossRefPubMed Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol. 2006;28(5):300–6.CrossRefPubMed
14.
go back to reference Cheng G, Servaes S, Zhuang H. Value of (18)F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma. Leuk Lymphoma. 2013;54(4):737–42.CrossRefPubMed Cheng G, Servaes S, Zhuang H. Value of (18)F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma. Leuk Lymphoma. 2013;54(4):737–42.CrossRefPubMed
15.
go back to reference Hasenclever D, Kurch L, Mauz-Körholz C, et al. qPET—a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(7):1301–8.CrossRefPubMed Hasenclever D, Kurch L, Mauz-Körholz C, et al. qPET—a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(7):1301–8.CrossRefPubMed
16.
go back to reference Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
17.
go back to reference Stauss J, Franzius C, Pfluger T, et al. Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2008;35(8):1581–8.CrossRefPubMed Stauss J, Franzius C, Pfluger T, et al. Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2008;35(8):1581–8.CrossRefPubMed
18.
go back to reference Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118(1):37–43.CrossRefPubMed Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118(1):37–43.CrossRefPubMed
19.
go back to reference Lin C, Itti E, Haioun C, Petegnief Y, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48(10):1626–32.CrossRefPubMed Lin C, Itti E, Haioun C, Petegnief Y, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48(10):1626–32.CrossRefPubMed
20.
go back to reference Itti E, Meignan M, Berriolo-Riedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax. Eur J Nucl Med Mol Imaging. 2013;40(9):1312–20.CrossRefPubMed Itti E, Meignan M, Berriolo-Riedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax. Eur J Nucl Med Mol Imaging. 2013;40(9):1312–20.CrossRefPubMed
21.
go back to reference Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51(9):1337–43.CrossRefPubMed Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51(9):1337–43.CrossRefPubMed
22.
go back to reference Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 18F-FDG positron emission tomography is prognostically superior to international prognostic score in advanced stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;24:3746–52.CrossRef Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 18F-FDG positron emission tomography is prognostically superior to international prognostic score in advanced stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;24:3746–52.CrossRef
23.
go back to reference Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, et al. Early interim18 F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging. 2012;39(1):4–12.CrossRefPubMed Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, et al. Early interim18 F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging. 2012;39(1):4–12.CrossRefPubMed
24.
go back to reference Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med. 2005;35(3):186–96.CrossRefPubMed Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med. 2005;35(3):186–96.CrossRefPubMed
25.
go back to reference Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG- PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16(7):1160–8.CrossRefPubMed Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG- PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16(7):1160–8.CrossRefPubMed
26.
go back to reference Furth C, Steffen IG, Amthauer H, Ruf J, Misch D, Schönberger S, et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron tomography in pediatric Hodgkin’s lymphoma: analysis of a prospective multicenter trial. J Clin Oncol. 2009;27(26):4385–91.CrossRefPubMed Furth C, Steffen IG, Amthauer H, Ruf J, Misch D, Schönberger S, et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron tomography in pediatric Hodgkin’s lymphoma: analysis of a prospective multicenter trial. J Clin Oncol. 2009;27(26):4385–91.CrossRefPubMed
27.
go back to reference Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2004;31(1):22–8.CrossRefPubMed Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2004;31(1):22–8.CrossRefPubMed
28.
go back to reference Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50(4):527–33.CrossRefPubMed Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50(4):527–33.CrossRefPubMed
29.
go back to reference Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited stage Hodgkin’s lymphoma. Ann Oncol. 2011;22(4):910–5.CrossRefPubMed Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited stage Hodgkin’s lymphoma. Ann Oncol. 2011;22(4):910–5.CrossRefPubMed
30.
go back to reference Pilkington Woll JP, García Vicente AM, Talavera Rubio MP, Palomar Muñoz AM, Jiménez Londoño G, León Martín A, et al. Quantitative and qualitative evaluation of the interim PET/CT in lymphoma treatment in the prediction of complete metabolic response. Rev Esp Med Nucl Imagen Mol. 2013;32(2):70–6.PubMed Pilkington Woll JP, García Vicente AM, Talavera Rubio MP, Palomar Muñoz AM, Jiménez Londoño G, León Martín A, et al. Quantitative and qualitative evaluation of the interim PET/CT in lymphoma treatment in the prediction of complete metabolic response. Rev Esp Med Nucl Imagen Mol. 2013;32(2):70–6.PubMed
Metadata
Title
Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18FDG-PET/CT according to ΔSUVmax, Deauville 5-point scale and IHP criteria
Authors
Emine Göknur Isik
Serkan Kuyumcu
Rejin Kebudi
Yasemin Sanli
Zeynep Karakas
Fatma Betul Cakir
Seher Nilgün Unal
Publication date
01-11-2017
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 9/2017
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-017-1196-x

Other articles of this Issue 9/2017

Annals of Nuclear Medicine 9/2017 Go to the issue